NICE (UK) positive for Beyonttra (acoramidis) for treating transthyretin amyloidosis with cardiomyopathy – Bayer
NICE(UK): Acoramidis can be used, within its marketing authorisation, as an option to treat wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.
Acoramidis can only be used if the company provides it according to the commercial arrangement.
Why these recommendations were made: Usual treatment for transthyretin amyloidosis with cardiomyopathy is tafamidis. Acoramidis works in a similar way to tafamidis and would be offered to the same population. Clinical trial evidence suggests that acoramidis is more effective than placebo. Acoramidis has not been directly compared in a clinical trial with tafamidis, but an indirect comparison suggests that they are likely to have similar clinical effectiveness. There are uncertainties with the clinical-effectiveness evidence, including: i) how effective acoramidis is in people with severe heart failure, and ii) that some people in the trial had both acoramidis and tafamidis. But these uncertainties are unlikely to have affected the overall results. A cost comparison suggests that the costs for acoramidis are similar to or lower than those for tafamidis. So, acoramidis can be used.
